+

US20020031781A1 - Signal enhancement of bispecific antibody-polymer probe for immunoassay use - Google Patents

Signal enhancement of bispecific antibody-polymer probe for immunoassay use Download PDF

Info

Publication number
US20020031781A1
US20020031781A1 US09/380,168 US38016899A US2002031781A1 US 20020031781 A1 US20020031781 A1 US 20020031781A1 US 38016899 A US38016899 A US 38016899A US 2002031781 A1 US2002031781 A1 US 2002031781A1
Authority
US
United States
Prior art keywords
antibody
probe
polymer
bispecific antibody
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/380,168
Other versions
US6451980B1 (en
Inventor
Ban-an Khaw
Jagat Narula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KHAW DR BAN-AN
Akrivis Technologies LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/380,168 priority Critical patent/US6451980B1/en
Application filed by Individual filed Critical Individual
Assigned to KHAW, BAN-AN reassignment KHAW, BAN-AN ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NARULA, JAGAT
Priority to US09/727,421 priority patent/US20010024795A1/en
Assigned to BIOSPECIFIC LLC reassignment BIOSPECIFIC LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KHAW, DR. BAN-AN,
Priority to US10/071,397 priority patent/US20020119582A1/en
Publication of US20020031781A1 publication Critical patent/US20020031781A1/en
Publication of US6451980B1 publication Critical patent/US6451980B1/en
Application granted granted Critical
Assigned to KHAW, DR. BAN-AN reassignment KHAW, DR. BAN-AN ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOSPECIFIC LLC
Assigned to KHAW, DR. BAN-AN reassignment KHAW, DR. BAN-AN ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOSPECIFIC LLC
Assigned to AKRIVIS TECHNOLOGIES, LLC reassignment AKRIVIS TECHNOLOGIES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KHAW, BAN-AN
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/817—Enzyme or microbe electrode
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/912—Absidia

Definitions

  • An immunoassay utilizes antibodies to detect a compound of choice.
  • the sensitivity of this detection is generally limited by the amount of signal that can be carried either on the antibody, for a direct binding assay, or on the probe compound, in a competitive inhibition assay.
  • existing immunoassays such as radioimmunoassay, ELISA, immunofluorescent assays or immunochemiluminescent assays
  • too many signal entities such as radioisotopes, horse radish peroxidase or alkaline phosphatase, attached to the detection moieties invariably inactivate the antibody or denature the antigen and change the property of the detection probe. Therefore, in order to obtain more signal, additional antibody or probe must be added. This, in turn, reduces the sensitivity of the assay, the capability of the assay to detect minute quantities of the compound in question.
  • the invention is directed to a method to increase the sensitivity of an immunoassay, by at least 10,000 fold, without losing specificity. This improvement is achieved by the use of a bispecific antibody complex and a unique detection signal probe capable of recognizing the bispecific antibody complex.
  • the invention features an immunoassay method including reacting a sample from a patient with a bispecific antibody, wherein the bispecific antibody includes one antibody specific for a compound to be detected and a second antibody specific for a compound foreign to said patient sample, and subsequently reacting the patient sample with a polymer probe, wherein the polymer probe includes a compound recognized by the second antibody in the bispecific antibody complex and further includes at least two detectable signals.
  • the invention also features the bispecific antibody and the polymer probe of the method of the invention.
  • the sample from the patient is a blood or serum sample;
  • the bispecific antibody includes an antimyosin antibody and an antibody against DTPA;
  • the polymer probe is a polylysine polymer and includes DTPA and at least six HRP as the detectable signal compounds.
  • FIG. 1 a shows a standard ELISA according to the prior art
  • FIG. 1 b shows an immunoassay according to the invention
  • FIG. 2 is a graph showing competitive inhibition curves using standard ELISA (R11D10), bispecific antibody complex with standard secondary antibody for signal production (BiMAb (Ab-HRP)), and the method according to the invention (BiMAb(PL-DTPA-HRP)).
  • the invention is directed to the development of a new approach to the use of bispecific antibodies in immunoassays.
  • the new specific antibody comprises one antibody specific for the compound associated with the pathological state to be detected and another antibody to a chemical or reporter compound that is not found naturally in man. These two are chemically or genetically linked.
  • the bispecific antibody complex constitutes the first line of interaction with the compound one is attempting to detect. Normally many antibodies must react with the compound to enable development of sufficient signal intensity for detection.
  • a novel detection probe is used, made up of any type polymer, such as polylysine or other polyamino acid, that is amenable to attachment of signal reagents and reporter compounds.
  • the amount of signal reagent that can be used in a given assay is limited only by the size of the polymer. Only a few molecules of the detection probe are therefore needed to provide this signal.
  • the signal probe is extremely versatile as any type of signal producing compound such as radioactivity, chemical color producing enzymes or fluorescent probes can be attached to the polymer backbone. Signal amplification is not limited by the nature of the bispecific antibody complex itself.
  • the immunoassay sensitivity can be amplified by at least 10,000-fold compared to conventional immunoassays or immunosandwich assays. Since early detection of many pathological states, such as acute myocardial infarction and cancer, is limited by the sensitivity of immunoassays to detect minute elevations of the pathologically associated compounds, an method and compounds of the invention will enable diagnosis of disease states at a much earlier time than previous assays, which may allow for better therapeutic intervention.
  • Another advantage of the method of the invention is the versatility for adaptation to any antibody.
  • the method could be adapted to detect troponin-I or T by using the antibody specific for troponin-I or T attached to a second antibody, such as the antibodies shown herein, that recognizes the detector probe. If higher sensitivity is necessary, the polymer probe could be generated to carry higher numbers of signal compounds.
  • the polymer probe can include any kind of signal compound, such as radioisotope, fluorescent, or paramagnetic linked signal compounds.
  • Serum immunoassays for intracardiac contractile proteins constitute the mainstay for detection of myocyte necrosis associated with various cardiovascular disorders.
  • myosin heavy chain (MHC) fragments can be detected by immunoassay only after 48 h from the onset of chest pain.
  • MAb monoclonal antibody
  • MAb 4G4-1D5 specific for DTPA.
  • the probe consisted of DTPA-modified polylysine (28:1 molar ratio) covalently linked to horse-radish peroxidase (6 moles/mole polylysine)(PL-DTPA-HRP).
  • Porcine cardiac myosin (PCM, 1 ⁇ g/ml) was used to coat the microtiter wells. After overnight incubation and washing, three times, 50 ⁇ l each of 5 ⁇ g/ml BiMAbor MAb and serial dilutions of PCM (0.001 to 100 ⁇ g/ml) or 50 ⁇ l of serial dilutions (1/1 to 1/10000) of patient sera pre-incubated for 1 h at 37° C. were added and incubated for 2 h at 37° C. After washing, the wells were incubated with goat-antimouse IgG-HRP or PL-DTPA-HRP for 2 h. A chromogen, dinitrobenzidine was used to develop the assay.
  • PCM Porcine cardiac myosin
  • BiMAb and R11D10 were the same at 1.5 ⁇ 10 9 L/mole.
  • the sensitivity of BiMAb was 0.5 ng, whereas that of R11D10 was 0.5 ⁇ g (1 ⁇ g/ml)
  • BiMAb developed with the conventional goat anti-mouse IgG-HRP had a sensitivity of 0.05 ⁇ g. Therefore, BiMAb assay has a 1000 fold increase in sensitivity compared to the conventional immunoassay in the sera of 3 heart transplant patients. Using the BiMAb assay, 2.5, 1.25 and 1.3 ng MHC/50 ⁇ l serum at 1/10 3 dilution, were detected.
  • This BiMAb technology can be used in RIA or ELISA by interchanging the HRP probe for radiolabeled probe and should provide more specific in vitro diagnosis of acute myocardial infarction since detection of MHC is not feasible at the present time of day 1 of myocardial infarction by conventional immunoassays.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

An immunoassay method including reacting a sample from a patient with a bispecific antibody, wherein the bispecific antibody includes one antibody specific for a compound to be detected and a second antibody specific for a compound foreign to said patient sample, and subsequently reacting the patient sample with a polymer probe, wherein the polymer probe includes a compound recognized by the second antibody in the bispecific antibody complex and further includes at least two detectable signals; the bispecific antibody; and the polymer probe of the immunoassay method are disclosed.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT BACKGROUND OF THE INVENTION
  • An immunoassay utilizes antibodies to detect a compound of choice. However, the sensitivity of this detection is generally limited by the amount of signal that can be carried either on the antibody, for a direct binding assay, or on the probe compound, in a competitive inhibition assay. For example, in existing immunoassays, such as radioimmunoassay, ELISA, immunofluorescent assays or immunochemiluminescent assays, too many signal entities, such as radioisotopes, horse radish peroxidase or alkaline phosphatase, attached to the detection moieties invariably inactivate the antibody or denature the antigen and change the property of the detection probe. Therefore, in order to obtain more signal, additional antibody or probe must be added. This, in turn, reduces the sensitivity of the assay, the capability of the assay to detect minute quantities of the compound in question. [0001]
  • For all existing immunoassays, there is lag time for the compound of interest to reach a high enough concentration in the serum to become detectable for diagnostic purposes. In the case of heart attacks, there is a delay of 4-6 hours from the onset of chest pain until the diagnostic detection of CKMB, Troponin-T or I is possible. Myoglobin is detectable earlier, but its specificity is low. If there were an assay that could detect very minute increases of these indicator compounds in the blood at an earlier point in time, then therapeutic intervention could be started earlier and thereby bring about greater myocardial salvage. In the case of cancer detection, where, e.g., tumor associated antigens related to breast cancer or colon cancer, etc., are detected, treatment might be more effective if minute elevations of these antigens could be detected at an early stage. Therefore, there is a need to increase the sensitivity of the assay without adversely affecting the specificity of the assay system. [0002]
    • SUMMARY OF THE INVENTION
  • The invention is directed to a method to increase the sensitivity of an immunoassay, by at least 10,000 fold, without losing specificity. This improvement is achieved by the use of a bispecific antibody complex and a unique detection signal probe capable of recognizing the bispecific antibody complex. [0003]
  • In one aspect, the invention features an immunoassay method including reacting a sample from a patient with a bispecific antibody, wherein the bispecific antibody includes one antibody specific for a compound to be detected and a second antibody specific for a compound foreign to said patient sample, and subsequently reacting the patient sample with a polymer probe, wherein the polymer probe includes a compound recognized by the second antibody in the bispecific antibody complex and further includes at least two detectable signals. The invention also features the bispecific antibody and the polymer probe of the method of the invention. Preferably, the sample from the patient is a blood or serum sample; the bispecific antibody includes an antimyosin antibody and an antibody against DTPA; and the polymer probe is a polylysine polymer and includes DTPA and at least six HRP as the detectable signal compounds.[0004]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof and from the claims, taken in conjunction with the accompanying drawings, in which: [0005]
  • FIG. 1[0006] a shows a standard ELISA according to the prior art;
  • FIG. 1[0007] b shows an immunoassay according to the invention; and
  • FIG. 2 is a graph showing competitive inhibition curves using standard ELISA (R11D10), bispecific antibody complex with standard secondary antibody for signal production (BiMAb (Ab-HRP)), and the method according to the invention (BiMAb(PL-DTPA-HRP)).[0008]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The invention is directed to the development of a new approach to the use of bispecific antibodies in immunoassays. The new specific antibody comprises one antibody specific for the compound associated with the pathological state to be detected and another antibody to a chemical or reporter compound that is not found naturally in man. These two are chemically or genetically linked. The bispecific antibody complex constitutes the first line of interaction with the compound one is attempting to detect. Normally many antibodies must react with the compound to enable development of sufficient signal intensity for detection. However, in the method of the invention, a novel detection probe is used, made up of any type polymer, such as polylysine or other polyamino acid, that is amenable to attachment of signal reagents and reporter compounds. The amount of signal reagent that can be used in a given assay is limited only by the size of the polymer. Only a few molecules of the detection probe are therefore needed to provide this signal. The signal probe is extremely versatile as any type of signal producing compound such as radioactivity, chemical color producing enzymes or fluorescent probes can be attached to the polymer backbone. Signal amplification is not limited by the nature of the bispecific antibody complex itself. [0009]
  • Therefore, the immunoassay sensitivity can be amplified by at least 10,000-fold compared to conventional immunoassays or immunosandwich assays. Since early detection of many pathological states, such as acute myocardial infarction and cancer, is limited by the sensitivity of immunoassays to detect minute elevations of the pathologically associated compounds, an method and compounds of the invention will enable diagnosis of disease states at a much earlier time than previous assays, which may allow for better therapeutic intervention. [0010]
  • Another advantage of the method of the invention is the versatility for adaptation to any antibody. For example, the method could be adapted to detect troponin-I or T by using the antibody specific for troponin-I or T attached to a second antibody, such as the antibodies shown herein, that recognizes the detector probe. If higher sensitivity is necessary, the polymer probe could be generated to carry higher numbers of signal compounds. Furthermore, the polymer probe can include any kind of signal compound, such as radioisotope, fluorescent, or paramagnetic linked signal compounds. [0011]
  • All previously existing ELISA radioimmunoassays, dip-stick assays for cancer, pregnancy, serum enzymes and probes and any assays utilizing antibodies could be modified according to the method of the invention to provide enhanced sensitivity. In addition, in vivo application to enhance target signal by using the method of the invention is also possible. [0012]
  • The following examples are presented to illustrate the advantages of the present invention and to assist one of ordinary skill in making and using the same. These examples are not intended in any way otherwise to limit the scope of the disclosure. [0013]
    • EXAMPLE I
  • Serum immunoassays for intracardiac contractile proteins constitute the mainstay for detection of myocyte necrosis associated with various cardiovascular disorders. However, myosin heavy chain (MHC) fragments can be detected by immunoassay only after 48 h from the onset of chest pain. To enhance immunodetection of MHC, monoclonal antibody (MAb) R11D10 specific for cardiac MHC was covalently linked to MAb 4G4-1D5 specific for DTPA. The probe consisted of DTPA-modified polylysine (28:1 molar ratio) covalently linked to horse-radish peroxidase (6 moles/mole polylysine)(PL-DTPA-HRP). Porcine cardiac myosin (PCM, 1 μg/ml) was used to coat the microtiter wells. After overnight incubation and washing, three times, 50 μl each of 5 μg/ml BiMAbor MAb and serial dilutions of PCM (0.001 to 100 μg/ml) or 50 μl of serial dilutions (1/1 to 1/10000) of patient sera pre-incubated for 1 h at 37° C. were added and incubated for 2 h at 37° C. After washing, the wells were incubated with goat-antimouse IgG-HRP or PL-DTPA-HRP for 2 h. A chromogen, dinitrobenzidine was used to develop the assay. The affinity of BiMAb and R11D10 were the same at 1.5×10[0014] 9 L/mole. The sensitivity of BiMAb was 0.5 ng, whereas that of R11D10 was 0.5 μg (1 μg/ml) BiMAb developed with the conventional goat anti-mouse IgG-HRP had a sensitivity of 0.05 μg. Therefore, BiMAb assay has a 1000 fold increase in sensitivity compared to the conventional immunoassay in the sera of 3 heart transplant patients. Using the BiMAb assay, 2.5, 1.25 and 1.3 ng MHC/50 μl serum at 1/103 dilution, were detected. This BiMAb technology can be used in RIA or ELISA by interchanging the HRP probe for radiolabeled probe and should provide more specific in vitro diagnosis of acute myocardial infarction since detection of MHC is not feasible at the present time of day 1 of myocardial infarction by conventional immunoassays.
    • EXAMPLE II
  • In a subsequent experiment the DTPA-modified polylysine probe of Example I was covalently linked to 12 moles of horse-radish peroxidase per mole of polylysine. The results of the study show that the sensitivity of the bispecific assay of the invention (10[0015] −5 to 100 μg/ml) was at least 10,000 fold better than the conventional immunoassay (0.1 μg/ml).
  • While the present invention has been described in conjunction with a preferred embodiment, one of ordinary skill, after reading the foregoing specification, will be able to effect various changes, substitutions of equivalents, and other alterations to the compositions and methods set forth herein. It is therefore intended that the protection granted by Letters Patent hereon be limited only by the definitions contained in the appended claims and equivalents thereof. [0016]

Claims (6)

What is claimed is:
1. An immunoassay method comprising
reacting a sample from a patient with a bispecific antibody, said bispecific antibody comprising
one antibody specific for a compound to be detected and
a second antibody specific for a compound foreign to said patient sample; and
subsequently reacting said sample with a polymer probe, said polymer probe comprising
a polymer backbone,
attached to said polymer backbone, a compound recognizable by said second antibody in said bispecific antibody, and
at least two detectable signal compounds further attached to said polymer backbone.
2. The immunoassay method of claim 1, wherein said polymer probe comprises at least ten detectable compounds.
3. The immunoassay method of claim 1, wherein said detectable signal in said polymer probe is selected from the group consisting of radioisotope, fluorescent probe and paramagnetic probe.
4. The immunoassay method of claim 1, wherein said sample from said patient is a blood or serum sample; said bispecific antibody comprises an antimyosin antibody and an antibody against DTPA; and said polymer probe is a polylysine polymer and comprises DTPA and at least 6 HRP as said detectable signal compounds.
5. A bispecific antibody for use in an immunoassay comprising
one antibody specific for a compound to be detected in said immunoassay; and
a second antibody specific for a compound foreign to a sample to be assayed in said immunoassay.
6. A polymer probe comprising
a polymer backbone;
attached to said polymer backbone, a compound recognizable by an antibody in a bispecific antibody; and
at least two detectable signal compounds attached to said polymer backbone.
US09/380,168 1997-02-26 1998-02-25 Signal enhancement of bispecific antibody-polymer probe for immunoassay use Expired - Lifetime US6451980B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/380,168 US6451980B1 (en) 1997-02-26 1998-02-25 Signal enhancement of bispecific antibody-polymer probe for immunoassay use
US09/727,421 US20010024795A1 (en) 1997-02-26 2000-12-01 Immunoassay technique using multispecific molecules
US10/071,397 US20020119582A1 (en) 1997-02-26 2002-02-06 Signal enhancement of bispecific antibody-polymer probe for immunoassay use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3911197P 1997-02-26 1997-02-26
PCT/US1998/003638 WO1998038513A1 (en) 1997-02-26 1998-02-25 Signal enhancement of bispecific antibody-polymer probe for immunoassay use
US09/380,168 US6451980B1 (en) 1997-02-26 1998-02-25 Signal enhancement of bispecific antibody-polymer probe for immunoassay use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/727,421 Continuation-In-Part US20010024795A1 (en) 1997-02-26 2000-12-01 Immunoassay technique using multispecific molecules
US10/071,397 Division US20020119582A1 (en) 1997-02-26 2002-02-06 Signal enhancement of bispecific antibody-polymer probe for immunoassay use

Publications (2)

Publication Number Publication Date
US20020031781A1 true US20020031781A1 (en) 2002-03-14
US6451980B1 US6451980B1 (en) 2002-09-17

Family

ID=21903743

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/380,168 Expired - Lifetime US6451980B1 (en) 1997-02-26 1998-02-25 Signal enhancement of bispecific antibody-polymer probe for immunoassay use
US10/071,397 Abandoned US20020119582A1 (en) 1997-02-26 2002-02-06 Signal enhancement of bispecific antibody-polymer probe for immunoassay use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/071,397 Abandoned US20020119582A1 (en) 1997-02-26 2002-02-06 Signal enhancement of bispecific antibody-polymer probe for immunoassay use

Country Status (3)

Country Link
US (2) US6451980B1 (en)
EP (1) EP0981748A4 (en)
WO (1) WO1998038513A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019820A1 (en) * 2003-08-25 2005-03-03 Marc Ramael A method and kit for the quantitative and/or qualitative detection of components in a sample
WO2005022150A3 (en) * 2003-09-01 2005-08-04 Selective Antibodies Ltd Assay methods and materials for distinguishing analytes and analyte analogues
EP2185725A4 (en) * 2007-08-02 2011-01-12 Biodesic Compositions and methods for analyte detection and quantitation
WO2011003780A1 (en) * 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
EP3465204A4 (en) * 2016-05-25 2019-12-25 Kromnigon AB PROCESS FOR THE PREPARATION OF A BIOLOGICAL SAMPLE FOR USE IN AN IMMUNOGAGING PROCESS

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753189B1 (en) 1998-06-04 2004-06-22 Mizuho Medy Co., Ltd. Detection apparatus and method for the same
GB9819411D0 (en) * 1998-09-04 1998-10-28 Ks Biomedix Ltd Antibodies
AU2002210384B2 (en) * 2000-10-17 2006-10-19 Besst-Test Aps Assay for directly detecting a RS virus related biological cell in a body fluid sample
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7473548B2 (en) 2003-04-25 2009-01-06 Medtronic, Inc. Optical detector for enzyme activation
JP5026072B2 (en) * 2003-07-01 2012-09-12 イミューノメディクス、インコーポレイテッド Multispecific carrier of bispecific antibody
EP2091975A4 (en) * 2006-11-21 2013-05-22 Univ California ANTI-EGFR FAMILY ANTIBODIES, BISPECIFIC ANTI-EGFR FAMILY ANTIBODIES AND METHODS OF USE THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223242A (en) 1985-11-05 1993-06-29 The General Hospital Corporation Negatively charged specific affinity reagents
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
AU5853590A (en) * 1989-06-14 1991-01-08 General Hospital Corporation, The Assay for human ventricular myosin lc1 and monoclonal antibody thereto
DE3920358A1 (en) * 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
AU1929292A (en) * 1991-05-14 1992-12-30 Hybritech Incorporated Polymeric compositions having bound antibodies
AU5729294A (en) * 1992-11-25 1994-06-22 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510881B2 (en) 2003-08-25 2009-03-31 Marc Ramael Method and kit for the quantitative and/or qualitative detection of components in a sample
WO2005019820A1 (en) * 2003-08-25 2005-03-03 Marc Ramael A method and kit for the quantitative and/or qualitative detection of components in a sample
US20060286546A1 (en) * 2003-08-25 2006-12-21 Marc Ramael Method and kit for the quantitative and/or qualitative detection of components in a sample
US8062855B2 (en) 2003-09-01 2011-11-22 Selective Antibodies Limited Assay methods and materials
WO2005022150A3 (en) * 2003-09-01 2005-08-04 Selective Antibodies Ltd Assay methods and materials for distinguishing analytes and analyte analogues
US20070178543A1 (en) * 2003-09-01 2007-08-02 Self Colin H Assay methods and materials
EP2185725A4 (en) * 2007-08-02 2011-01-12 Biodesic Compositions and methods for analyte detection and quantitation
JP2012532174A (en) * 2009-07-06 2012-12-13 エフ．ホフマン−ラ ロシュ アーゲー Bispecific digoxigenin binding antibody
WO2011003557A1 (en) * 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
CN102481367A (en) * 2009-07-06 2012-05-30 弗·哈夫曼-拉罗切有限公司 Digoxigenin-binding bispecific antibody
WO2011003780A1 (en) * 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
US8907069B2 (en) 2009-07-06 2014-12-09 Hoffmann-La Roche Inc. Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
EP2823821A1 (en) * 2009-07-06 2015-01-14 F. Hoffmann-La Roche AG Antibody specifically binding to digoxigenin
CN102481367B (en) * 2009-07-06 2015-04-29 弗·哈夫曼-拉罗切有限公司 Bi-specific digoxigenin binding antibodies
US9050375B2 (en) 2009-07-06 2015-06-09 Hoffmann-La Roche, Inc. Bi-specific digoxigenin binding antibodies
US9574016B2 (en) 2009-07-06 2017-02-21 Hoffmann-La Roche Inc. Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
EP3465204A4 (en) * 2016-05-25 2019-12-25 Kromnigon AB PROCESS FOR THE PREPARATION OF A BIOLOGICAL SAMPLE FOR USE IN AN IMMUNOGAGING PROCESS
US11340218B2 (en) 2016-05-25 2022-05-24 Kromnigon Ab Method for preparing a biological sample for use in an immunolabeling process

Also Published As

Publication number Publication date
EP0981748A1 (en) 2000-03-01
EP0981748A4 (en) 2002-09-18
US6451980B1 (en) 2002-09-17
WO1998038513A1 (en) 1998-09-03
US20020119582A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
US5914241A (en) Assays and kits for detecting analytes in the presence of cross-reacting substances
US4731326A (en) Disease diagnosis by detection of shed normal tissue antigens
US6451980B1 (en) Signal enhancement of bispecific antibody-polymer probe for immunoassay use
US20070166776A1 (en) Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample
JPS6120867A (en) Sandwich test for antibody-lectin
AU773595B2 (en) Diagnostic assay for stroke
JP3055789B2 (en) Assay for alkaline phosphatase from bone
WO2012175602A2 (en) Elisa for calprotectin
JP4334065B2 (en) Reduction of immunoassay interference by substances derived from the framework regions of antibodies.
EP0313244B1 (en) Method for increasing the sensitivity of assays for mucin
US6406858B1 (en) System for the reduction of interferences in immunoassays
JPH02124462A (en) Improved immunoassay
US20020187518A1 (en) Methods and devices for detecting non-complexed prostate specific antigen
WO1987002779A1 (en) Idiotypic-antigenic conjunction binding assay
EP0938678A1 (en) Method and kit for the diagnosis of troponin i
WO1990011526A1 (en) Cancer diagnosis
US5593898A (en) Diagnostic method for the immunological determination of NCAM
KR960011098B1 (en) Diagnosis method for assaying basic fetoprotein in urine
JP3470936B2 (en) Immunoassay method and its reagent
JP2000180447A (en) Judgment method and reagent for judging acute myocardial infarction
Guesdon Amplification systems for enzyme immunoassay
JP2520465B2 (en) Multi-labeled antibody
US5179000A (en) Method for assaying basic fetoprotein in urine and assay kit therefor
JP2024060569A (en) Biomarkers for detecting essential hypertension, detection method using the same, and detection reagent
JPH11326329A (en) Immunological method for determining prostate gland specific antigen

Legal Events

Date Code Title Description
AS Assignment

Owner name: KHAW, BAN-AN, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NARULA, JAGAT;REEL/FRAME:010997/0001

Effective date: 20000526

AS Assignment

Owner name: BIOSPECIFIC LLC, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KHAW, DR. BAN-AN,;REEL/FRAME:012035/0865

Effective date: 20010515

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: KHAW, DR. BAN-AN, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOSPECIFIC LLC;REEL/FRAME:015226/0322

Effective date: 20040405

Owner name: KHAW, DR. BAN-AN, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOSPECIFIC LLC;REEL/FRAME:015226/0374

Effective date: 20040405

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
AS Assignment

Owner name: AKRIVIS TECHNOLOGIES, LLC, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KHAW, BAN-AN;REEL/FRAME:023263/0174

Effective date: 20090312

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载